Evidence map›Paper›PMID 24937131›Full record

ArticlePloS one2014

The VMAT-2 inhibitor tetrabenazine affects effort-related decision making in a progressive ratio/chow feeding choice task: reversal with antidepressant drugs.

Patrick A Randall, Christie A Lee, Eric J Nunes, Samantha E Yohn, Victoria Nowak, Bilal Khan, Priya Shah, Saagar Pandit, V Kiran Vemuri, Alex Makriyannis and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 107 citations in OpenAlex.

  1. Effort, timing and choice: a refined rodent effort choice task with excellent sensitivity to dopamine modulators.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Potential therapeutics for effort-related motivational dysfunction: assessing novel atypical dopamine transport inhibitors.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Article
  13. Article
  14. Neuropsychological Effects of Antidepressants: Translational Studies.Current topics in behavioral neurosciences · 2024
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 4 countries.

Patrick A RandallDepartment of Psychology, University of Connecticut, Storrs, Connecticut, United States of America.
Christie A LeeDepartment of Psychology, University of Connecticut, Storrs, Connecticut, United States of America.
Eric J NunesDepartment of Psychology, University of Connecticut, Storrs, Connecticut, United States of America.
Samantha E YohnDepartment of Psychology, University of Connecticut, Storrs, Connecticut, United States of America.
Victoria NowakDepartment of Psychology, University of Connecticut, Storrs, Connecticut, United States of America.
Bilal KhanDepartment of Psychology, University of Connecticut, Storrs, Connecticut, United States of America.
Priya ShahDepartment of Psychology, University of Connecticut, Storrs, Connecticut, United States of America.
Saagar PanditDepartment of Psychology, University of Connecticut, Storrs, Connecticut, United States of America.
V Kiran VemuriCenter for Drug Discovery, Northeastern University, Boston, Massachusetts, United States of America.
Alex MakriyannisCenter for Drug Discovery, Northeastern University, Boston, Massachusetts, United States of America.
Younis BaqiPharma-Zentrum Bonn, Pharmazeutisches Institut, Pharmazeutische Chemie, Universität Bonn, Bonn, Germany; Department of Chemistry, Faculty of Science, Sultan Qaboos University, Muscat, Oman.
Christa E MüllerPharma-Zentrum Bonn, Pharmazeutisches Institut, Pharmazeutische Chemie, Universität Bonn, Bonn, Germany.
Merce CorreaDepartment of Psychology, University of Connecticut, Storrs, Connecticut, United States of America; Àrea de Psicobiologia, Campus de Riu Sec, Universitat Jaume I, Castelló, Spain.
John D SalamoneDepartment of Psychology, University of Connecticut, Storrs, Connecticut, United States of America.
University of Connecticut · USNortheastern University · USSultan Qaboos University · OMUniversitat Jaume I · ESUniversity of Bonn · DE

Funding

Cannabinergic Medications for Methamphetamine AddictionR37DA023142 · NIDA · NORTHEASTERN UNIVERSITY · PI MAKRIYANNIS, ALEXANDROS · 2007 to 2016
$7.1M
Development of rat models of the effort-related symptoms of depressionR03MH094966 · NIMH · UNIVERSITY OF CONNECTICUT STORRS · PI SALAMONE, JOHN D · 2012 to 2013
$151k
NIDA NIH HHS R37 DA023142NIMH NIH HHS MH094966NIMH NIH HHS R03 MH094966
6 · The paper itself

Abstract

Behavioral activation is a fundamental feature of motivation, and organisms frequently make effort-related decisions based upon evaluations of reinforcement value and response costs. Furthermore, people with major depression and other disorders often show anergia, psychomotor retardation, fatigue, and alterations in effort-related decision making. Tasks measuring effort-based decision making can be used as animal models of the motivational symptoms of depression, and the present studies characterized the effort-related effects of the vesicular monoamine transport (VMAT-2) inhibitor tetrabenazine. Tetrabenazine induces depressive symptoms in humans, and also preferentially depletes dopamine (DA). Rats were assessed using a concurrent progressive ratio (PROG)/chow feeding task, in which they can either lever press on a PROG schedule for preferred high-carbohydrate food, or approach and consume a less-preferred lab chow that is freely available in the chamber. Previous work has shown that the DA antagonist haloperidol reduced PROG work output on this task, but did not reduce chow intake, effects that differed substantially from those of reinforcer devaluation or appetite suppressant drugs. The present work demonstrated that tetrabenazine produced an effort-related shift in responding on the PROG/chow procedure, reducing lever presses, highest ratio achieved and time spent responding, but not reducing chow intake. Similar effects were produced by administration of the subtype selective DA antagonists ecopipam (D1) and eticlopride (D2), but not by the cannabinoid CB1 receptor neutral antagonist and putative appetite suppressant AM 4413, which suppressed both lever pressing and chow intake. The adenosine A2A antagonist MSX-3, the antidepressant and catecholamine uptake inhibitor bupropion, and the MAO-B inhibitor deprenyl, all reversed the impairments induced by tetrabenazine. This work demonstrates the potential utility of the PROG/chow procedure as a rodent model of the effort-related deficits observed in depressed patients.

Indexed as

AnimalsAntidepressive AgentsBenzazepinesBenzophenonesBupropionCannabinoid Receptor AntagonistsChoice BehaviorDepressionDopamine AntagonistsDrug Evaluation, PreclinicalFeeding BehaviorMaleNitrophenolsPyrazolesRats, Sprague-DawleySalicylamidesAM4113Antidepressive AgentsBenzazepinesBenzophenonesBupropionCannabinoid Receptor AntagonistsDopamine AntagonistsecopipameticloprideMSX 3 compoundNitrophenolsPyrazolesSalicylamidesSelegilineSlc18a2 protein, ratTetrabenazineTolcaponeVesicular Monoamine Transport ProteinsXanthines

Identifiers

PMID24937131
PMCPMC4061002
OpenAlexW1993869710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.